Evotec Establishes Integrated Communications and Investor Relations Leadership Role

Evotec Establishes Integrated Communications and Investor Relations Leadership Role

(IN BRIEF) Evotec SE has created a new Executive Vice President role that combines Global Communications and Investor Relations as part of a broader effort to strengthen strategic clarity and stakeholder engagement. Dr. Sarah Fakih has been appointed to lead the integrated function, reporting directly to CEO Dr. Christian Wojczewski. The leadership change follows the departure of Volker Braun after five years overseeing Investor Relations and ESG. With more than 15 years of life sciences experience and senior roles at companies such as QIAGEN, MorphoSys, and CureVac, Dr. Fakih is expected to play a central role in aligning Evotec’s scientific narrative, corporate strategy, and investor communications.

(PRESS RELEASE) HAMBURG, 2-Jan-2026 — /EuropaWire/ — Evotec SE has introduced a newly created executive leadership position that brings together Global Communications and Investor Relations, underscoring the company’s intent to sharpen strategic messaging and reinforce alignment with key stakeholders. Effective immediately, Dr. Sarah Fakih has been appointed Executive Vice President, Head of Global Communications and Investor Relations.

Based in Hamburg, Dr. Fakih will oversee the combined global function and report directly to Chief Executive Officer Dr. Christian Wojczewski. By unifying communications and investor relations under a single leadership structure, Evotec aims to ensure a more coherent and consistent narrative around its corporate strategy, scientific capabilities, and long-term value creation.

The move follows the departure of Volker Braun, who led Evotec’s Investor Relations and ESG activities for the past five years. During his tenure, the company strengthened its engagement with the investment community and advanced transparency across environmental, social, and governance topics.

Commenting on the appointment, Dr. Wojczewski emphasized the importance of trusted and precise communication as Evotec continues to execute its strategic priorities. He highlighted Dr. Fakih’s broad background spanning scientific expertise, capital markets, and corporate communications as key strengths that position her well to lead the integrated function, while also expressing appreciation for Mr. Braun’s contributions and wishing him success in his next chapter.

Dr. Fakih brings more than 15 years of experience in the life sciences sector, having held senior leadership roles at several U.S.-listed companies, including QIAGEN, MorphoSys, and most recently CureVac. She holds a PhD in Chemistry and is recognized for her work in shaping capital markets strategy and corporate messaging within complex, science-driven organizations.

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:
Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

SOURCE: Evotec